The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.

Twelve patients with rectal carcinoma were treated for 2 weeks with the somatostatin analogue SMS 201.995. Effects of this therapy were assessed using serum marker concentration, Ki67 and gastrin-immunoreactivity of the primary tumour. In four out of 12 patients, a significant decrease in Ki67 immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Iftikhar, S. Y., Watson, S. A., Morris, D. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972528/
https://www.ncbi.nlm.nih.gov/pubmed/2069853
_version_ 1782135024415408128
author Iftikhar, S. Y.
Watson, S. A.
Morris, D. L.
author_facet Iftikhar, S. Y.
Watson, S. A.
Morris, D. L.
author_sort Iftikhar, S. Y.
collection PubMed
description Twelve patients with rectal carcinoma were treated for 2 weeks with the somatostatin analogue SMS 201.995. Effects of this therapy were assessed using serum marker concentration, Ki67 and gastrin-immunoreactivity of the primary tumour. In four out of 12 patients, a significant decrease in Ki67 immunoreactivity was seen during SMS 201.995 treatment while in the remaining eight patients there was no significant change in Ki67 expression. Four patients had elevated pretreatment serum carcinoembryonic antigen (CEA) levels. In two of these four patients, serum CEA levels fell modestly during SMS 201.995 therapy. This is the first clinical evidence that a somatostatin analogue can inhibit the growth of some colorectal cancers.
format Text
id pubmed-1972528
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19725282009-09-10 The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer. Iftikhar, S. Y. Watson, S. A. Morris, D. L. Br J Cancer Research Article Twelve patients with rectal carcinoma were treated for 2 weeks with the somatostatin analogue SMS 201.995. Effects of this therapy were assessed using serum marker concentration, Ki67 and gastrin-immunoreactivity of the primary tumour. In four out of 12 patients, a significant decrease in Ki67 immunoreactivity was seen during SMS 201.995 treatment while in the remaining eight patients there was no significant change in Ki67 expression. Four patients had elevated pretreatment serum carcinoembryonic antigen (CEA) levels. In two of these four patients, serum CEA levels fell modestly during SMS 201.995 therapy. This is the first clinical evidence that a somatostatin analogue can inhibit the growth of some colorectal cancers. Nature Publishing Group 1991-06 /pmc/articles/PMC1972528/ /pubmed/2069853 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Iftikhar, S. Y.
Watson, S. A.
Morris, D. L.
The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.
title The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.
title_full The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.
title_fullStr The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.
title_full_unstemmed The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.
title_short The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.
title_sort effect of long acting somatostatin analogue sms 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972528/
https://www.ncbi.nlm.nih.gov/pubmed/2069853
work_keys_str_mv AT iftikharsy theeffectoflongactingsomatostatinanaloguesms201995therapyontumourkineticmeasurementsandserumtumourmarkerconcentrationsinprimaryrectalcancer
AT watsonsa theeffectoflongactingsomatostatinanaloguesms201995therapyontumourkineticmeasurementsandserumtumourmarkerconcentrationsinprimaryrectalcancer
AT morrisdl theeffectoflongactingsomatostatinanaloguesms201995therapyontumourkineticmeasurementsandserumtumourmarkerconcentrationsinprimaryrectalcancer
AT iftikharsy effectoflongactingsomatostatinanaloguesms201995therapyontumourkineticmeasurementsandserumtumourmarkerconcentrationsinprimaryrectalcancer
AT watsonsa effectoflongactingsomatostatinanaloguesms201995therapyontumourkineticmeasurementsandserumtumourmarkerconcentrationsinprimaryrectalcancer
AT morrisdl effectoflongactingsomatostatinanaloguesms201995therapyontumourkineticmeasurementsandserumtumourmarkerconcentrationsinprimaryrectalcancer

Ejemplares similares